repaglinide has been researched along with efavirenz in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kansra, V; Lu, S; Powers, D; Wang, J; Wang, X; Zhang, ZY | 1 |
| Akizawa, T; Endo, Y; Fukagawa, M; Kannami, A; Maeda, H; Nagata, Y; Nakamura, H; Narushima, K; Ohtsuka, S; Shimazaki, R; Shiramoto, M; Uchimura, T | 1 |
2 review(s) available for repaglinide and efavirenz
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for repaglinide and efavirenz
| Article | Year |
|---|---|
Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.
Topics: Administration, Oral; Adolescent; Adult; Alkynes; Antiemetics; Benzoxazines; Carbamates; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Dextromethorphan; Drug Combinations; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Middle Aged; Molecular Probes; Neurokinin-1 Receptor Antagonists; Omeprazole; Piperidines; Spiro Compounds; Tolbutamide; Young Adult | 2019 |
Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans.
Topics: Administration, Oral; Adult; Alkynes; Benzoxazines; Calcimimetic Agents; Carbamates; Cells, Cultured; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Healthy Volunteers; Hepatocytes; Humans; Hyperparathyroidism, Secondary; Inhibitory Concentration 50; Isoenzymes; Male; Naphthalenes; Oxidation-Reduction; Piperidines; Primary Cell Culture; Pyrrolidines; Theophylline; Young Adult | 2019 |
4 other study(ies) available for repaglinide and efavirenz
| Article | Year |
|---|---|
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |